HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Acyl-CoA Oxidase

An enzyme that catalyzes the first and rate-determining steps of peroxisomal beta-oxidation of fatty acids. It acts on COENZYME A derivatives of fatty acids with chain lengths from 8 to 18, using FLAVIN-ADENINE DINUCLEOTIDE as a cofactor.
Also Known As:
Acyl Coenzyme A Oxidase; Fatty Acid Acyl-CoA Oxidase; Fatty Acyl-CoA Oxidase; Fatty Acyl-Coenzyme A Oxidase; Acyl CoA Oxidase; Acyl-CoA Oxidase, Fatty; Fatty Acid Acyl CoA Oxidase; Fatty Acyl CoA Oxidase; Fatty Acyl Coenzyme A Oxidase; Oxidase, Acyl-CoA; Oxidase, Fatty Acyl-CoA
Networked: 106 relevant articles (0 outcomes, 7 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Reddy, J K: 6 articles (06/2012 - 03/2000)
2. Reddy, Janardan K: 5 articles (08/2011 - 01/2002)
3. Rao, M Sambasiva: 4 articles (08/2011 - 12/2002)
4. Cherkaoui-Malki, Mustapha: 3 articles (06/2012 - 10/2009)
5. Jia, Yuzhi: 3 articles (08/2011 - 12/2002)
6. Rao, M S: 3 articles (08/2001 - 03/2000)
7. Ai, Qinghui: 2 articles (02/2015 - 10/2013)
8. Zuo, Rantao: 2 articles (02/2015 - 10/2013)
9. Xu, Wei: 2 articles (02/2015 - 10/2013)
10. Mai, Kangsen: 2 articles (02/2015 - 10/2013)

Related Diseases

1. Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked)
02/01/1999 - "We found that expression of both acyl-CoA oxidase, the rate limiting enzyme of peroxisomal VLCFA beta-oxidation and the adrenoleukodystrophy protein (ALDP), the defective gene product in X-ALD, are reduced after SV40T transformation. "
06/03/1991 - "Immunoblot analyses of peroxisomal beta-oxidation enzymes showed that subunit A of acyl-CoA oxidase gave a stronger immunoreaction in fibroblasts of Zellweger and X-linked adrenoleukodystrophy patients than in those of controls. "
02/01/1999 - "Impaired peroxisomal beta-oxidation of saturated very long chain fatty acids (VLCFA, >/=C22:0) results in increased VLCFA levels in the tissues and body fluids of patients with disorders of peroxisomal biogenesis (i.e., Zellweger syndrome and neonatal adrenoleukodystrophy) and single peroxisomal protein defects (i.e., X-linked adrenoleukodystrophy (X-ALD) and acyl-CoA oxidase deficiency). "
06/01/2004 - "Additional studies in fibroblasts from patients with X-linked adrenoleukodystrophy, straight-chain acyl-CoA oxidase (SCOX) deficiency, d-bifunctional protein (DBP) deficiency, and rhizomelic chondrodysplasia punctata type 1, together with direct enzyme measurements with human recombinant l-bifunctional protein (LBP) and DBP expressed in a fox2 deletion mutant of Saccharomyces cerevisiae, show that the main enzymes involved in beta-oxidation of C16DCA are SCOX, both LBP and DBP, and sterol carrier protein X, possibly together with the classic 3-ketoacyl-CoA thiolase. "
12/01/2001 - "By making use of fibroblasts from patients with defined mitochondrial and peroxisomal fatty acid oxidation defects, we show in this article that peroxisomes, and not mitochondria, are involved in DHA formation by catalyzing the beta-oxidation of C24:6n-3 to C22:6n-3. Additional studies of fibroblasts from patients with X-linked adrenoleukodystrophy, straight-chain acyl-CoA oxidase (SCOX) deficiency, d-bifunctional protein (DBP) deficiency, and rhizomelic chondrodysplasia punctata type 1, and of fibroblasts from l-bifunctional protein and sterol carrier protein X (SCPx) knockout mice, show that the main enzymes involved in beta-oxidation of C24:6n-3 to C22:6n-3 are SCOX, DBP, and both 3-ketoacyl-CoA thiolase and SCPx. "
2. Obesity
3. Hepatocellular Carcinoma (Hepatoma)
4. Peroxisomal Disorders (Peroxisomal Disorder)
5. Metabolic Diseases (Metabolic Disease)

Related Drugs and Biologics

1. Enzymes
2. Catalase
3. type 1 Rhizomelic chondrodysplasia punctata
4. sterol carrier proteins
5. Messenger RNA (mRNA)
6. Coenzyme A (CoA)
7. Oxidoreductases
8. Fatty Acids (Saturated Fatty Acids)
9. Carnitine O-Palmitoyltransferase (Carnitine Palmitoyltransferase II)
10. Peroxisome Proliferator-Activated Receptors (PPAR)

Related Therapies and Procedures

1. Aftercare (After-Treatment)